PRX-102 for treating Fabry disease: immunogenicity and PK results from a phase 1-2 study

被引：2

作者：

Warnock, David ^{[1
]}

Hughes, Derralynn ^{[2
]}

Boyd, Simeon ^{[3
]}

Giraldo, Pilar ^{[4
]}

Gonzalez, Derlis ^{[5
]}

Holida, Myrl ^{[6
]}

Goker-Alpan, Ozlem ^{[7
]}

Maegawa, Gustavo ^{[8
]}

Atta, Mohamed ^{[9
]}

Nicholls, Kathy ^{[10
,11
]}

Schiffmann, Raphael ^{[12
]}

Tuffaha, Ahmad ^{[13
]}

Charney, Martha

Chertkoff, Raul ^{[14
]}

Alon, Sari ^{[15
]}

Brill-Almon, Einat ^{[15
]}

机构：

[1] UAB, Birmingham, AL USA

[2] UCL, London, England

[3] UC Davis Med Ctr, Sacramento, CA USA

[4] Hosp Dia Quiron, Zaragoza, Spain

[5] Inst Privado Hematol Invest Clin, Asuncion, Paraguay

[6] Univ Iowa, Iowa City, IA USA

[7] O&O Alpan LLC, Fairfax, VA USA

[8] Univ Florida, Gainesville, FL USA

[9] Johns Hopkins Univ, Sch Med, Baltimore, MD USA

[10] Royal Melbourne Hosp, Melbourne, Vic, Australia

[11] Univ Melbourne, Parkville, Vic, Australia

[12] Baylor Univ, Dallas, TX USA

[13] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA

[14] Protalix, Carmiel, AL USA

[15] Protalix, Carmiel, Israel

来源：

MOLECULAR GENETICS AND METABOLISM | 2017年 / 120卷 / 1-2期

关键词：

D O I：

10.1016/j.ymgme.2016.11.364

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

355

引用

页码：S137 / S138

页数：2

共 50 条

[1] Enhanced pharmacokinetics profile of pegunigalsidase alfa (PRX-102) supports once-monthly 2mg/kg dosing for the treatment of Fabry disease
Warnock, David G.
Charney, Martha R.
Hughes, Derralynn
Schiffmann, Raphael
Alon, Sari
Chertkoff, Raul
Brill-Almon, Einat
MOLECULAR GENETICS AND METABOLISM, 2018, 123 (02) : S145 - S146
[2] Sargramostim in patients with Crohn's disease: results of a phase 1-2 study
Takazoe, Masakazu
Matsui, Toshiyuki
Motoya, Satoshi
Matsumoto, Takayuki
Hibi, Toshifumi
Watanabe, Mamoru
JOURNAL OF GASTROENTEROLOGY, 2009, 44 (06) : 535 - 543
[3] Safety and pharmacokinetic (PK) results from phase 1 of an ongoing phase 1-2 study of onapristone (ONA) in patients (pts) with progesterone receptor (PR)-expressing cancers.
Italiano, Antoine
Bonneterre, Jacques
Varga, Andrea
Rezai, Keyvan
Campone, Mario
Floquet, Anne
Leary, Alexandra
Berton-Rigaud, Dominique
Sablin, Marie-Paule
Lesoin, Anne
Lokiec, Francois Marc
Lhomme, Catherine
Bexon, Alice Susannah
Gilles, Erard M.
Bisaha, Joseph
Zukiwski, Alexander
Cottu, Paul H.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[4] Phase 3 study of migalastat HCl for Fabry disease: Stage 1 results
Nicholls, Kathy
Germain, Dominique P.
Feliciani, Claudio
Shankar, Suma
Ezgu, Fatih
Janmohamed, Salim G.
Laing, Shiona M.
Schroyer, Rosemary O.
Bragat, Alex C.
Sitaraman, Sheela
Boudes, Pol F.
MOLECULAR GENETICS AND METABOLISM, 2013, 108 (02) : S70 - S70
[5] Immunogenicity to cerliponase alfa intracerebroventricular enzyme replacement therapy for CLN2 disease: Results from a Phase 1/2 study
Cherukuri, Anu
Cahan, Heather
de Hart, Greg
Van Tuyl, Andrea
Slasor, Peter
Bray, Laurie
Henshaw, Joshua
Ajayi, Temitayo
Jacoby, Dave
O'Neill, Charles A.
Schweighardt, Becky
CLINICAL IMMUNOLOGY, 2018, 197 : 68 - 76
[6] Immunogenicity to cerliponase alfa, an enzyme replacement therapy for patients with CLN2 disease: results from a phase 1/2 study
Cherukuri, Anu
Cahan, Heather
Van Tuyl, Andrea
de Hart, Greg
Slasor, Peter
Bray, Laurie
Henshaw, Josh
Ajayi, Temitayo
Jacoby, Dave
O'Neill, Charles
Schweighardt, Becky
MOLECULAR GENETICS AND METABOLISM, 2017, 120 (1-2) : S35 - S35
[7] Sargramostim treatment of pediatric Crohn's disease: Preliminary results of a phase 1-2 safety and pharmacokinetic study
Baldassano, Robert
Cohen, Stanley A.
Ferry, George D.
Heyman, Melvin B.
Rosh, Joel R.
Grossova-garie, Sona
Scholz, Catherine
Winter, Harland S.
GASTROENTEROLOGY, 2007, 132 (04) : A180 - A180
[8] Once every 4 weeks-2 mg/kg of pegunigalsidase alfa for treating Fabry disease Preliminary results of a phase 3 study
Holida, Myrl D.
Bernat, John
Longo, Nicola
Goker-Alpan, Ozlem
Wallace, Eric
Schiffmann, Raphael
Deegan, Patrick
Khan, Nedd
Tondel, Camilla
Eyskens, Francois
Hughes, Derralynn
West, Michael
Giraldo, Pilar
Ezgu, Fatih
Almon, Einat
Alon, Sari
Amit-Cohen, Bat-chen
Szlaifer, Mali
Chertkoff, Raul
Wilcox, William
MOLECULAR GENETICS AND METABOLISM, 2019, 126 (02) : S73 - S73
[9] Enzyme replacement therapy in Japanese Fabry disease patients: The results of a phase 2 bridging study
Eto, Y
Ohashi, T
Utsunomiya, Y
Fujiwara, M
Mizuno, A
Inui, K
Sakai, N
Kitagawa, T
Suzuki, Y
Mochizuki, S
Kawakami, M
Hosoya, T
Owada, M
Sakuraba, H
Saito, H
JOURNAL OF INHERITED METABOLIC DISEASE, 2005, 28 (04) : 575 - 583
[10] Isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease: Updated results from an ongoing phase 1/2 study (STAAR)
Hughes, Derralynn
Wilcox, William
Hopkin, Robert J.
Ganesh, Jaya
Bernat, John
Goker-Alpan, Ozlem
Nicholls, Kathy
Deegan, Patrick
Pahl, Madeleine
Whitley, Chester B.
Chen, Michael
Cao, Liching
Schreeb, Katharina H.
MOLECULAR GENETICS AND METABOLISM, 2025, 144 (02)

← 1 2 3 4 5 →